GENETIC TECHNOLOGIES LIMITED — AGM Information 2012

Nov 26, 2012

==> picture [595 x 72] intentionally omitted <==

==> picture [595 x 72] intentionally omitted <==

ASX ANNOUNCEMENT November 27[th] , 2012

2012 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by its Chief Executive Officer, Dr. Paul MacLeman, at the Company’s 2012 Annual General Meeting to be held at 11.00 am this morning in the “Treetops” Room at Melbourne Museum, 11 Nicholson Street, Carlton, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Thomas G. Howitt Company Secretary

Genetic Technologies Limited (ABN 17 009 212 328) Telephone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Genetic Technologies Limited Dr Paul MacLeman – CEO Address

Annual General Meeting Tuesday, 27 November 2012

This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward‐looking statements. By their nature, forward‐looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no

Goal

Outcome

Achieve BREVAGen™ business targets

‐ BREVAGen™ clinical trials and expanded label claim

‐ Expand in major new geographies (CA & FL)

‐ Expansion of reimbursement agreements and

• ongoing

� �

‘insured lives’ covered

Maximize licensing opportunities

• New US strategy

‐ New EU approach

• ongoing

• ongoing

==> picture [721 x 449] intentionally omitted <==

----- Start of picture text -----

BREVAGen™ Success to Date
2011 2012
April June Feb. April May July August September October
Credentialing
CMS CLIA CMS CLIA Contracts European
Registration Certificate 4 of Top 10 CE Mark
of US PPOs Approval
Compliance
US Pilot PacRim California Florida US TV &
Launch Pilot Approval to Approval to Media
Launch Sell Sell Coverage
----- End of picture text -----

BREVAGen™ Territory Expansion

Peer companies: Plot of revenues against announcements by year from launch

Myriad Genetics Genomic Health

Initial target markets: biopsy negative and BRCA negative women => estimated 1.2m patients or $600m/annum

Seeing use in annual ‘well woman’ exam (70m OBGYN office visits/annum, 2006):

• Physicians using to baseline risk at 40y.o.

• Prescribing more tests per week than anticipated once gain

• Performance/payments per patient to date 20‐25% better than initially budgeted

• PPO credentialing under way (13m covered lives to date)

• More expected in the coming quarters

• Coverage negotiations to commence CY2013

• CPT Coding changes anticipated in 2013,

• Approximately 20 projects reviewed this year

• Detailed due diligence undertaken on three

• One project now at late negotiation stage: pipeline of 2‐4 women’s health diagnostics

• Another larger transaction at earlier DD stage

Project attributes sought are:

• Near to or on market

• Good fit to GTG’s US sales channels (OBGYNs/oncologists/breast surgeons)

• High unmet medical need and large addressable market

• 1,700 infringing parties available in database

• Many more years of available licensing

• USA expanded contact with more parties

• Large settlement expected soon

• Renewed strategy in EU leveraging all our advisors’ expertise and experience

• New suits against direct infringers this quarter

• Expect ‘179 to be re‐issued following re‐examination at USPTO substantially unchanged

• Australian sales 98% of budget

• New or renewed contacts:

• Paternity

• Forensics

• Canine

• Expanded distribution private paternity

• Initial launch BREVAGen

• National media Ch7

1. Expanded US territory reach

1. New products / geographies under development

2. Expanded covered lives in US 4. Expanded BREVAGen publications

Company performance for 2011/12 period

• CLIA registration 49/50 states

• BREVAGen launched, sales growing, pleasing

• reimbursement

• Licensing moving ahead strongly

Recent US and Australian Media

Dr Paul D R MacLeman CEO Genetic Technologies Ltd Phone +61 3 8412 7000 Email info@gtglabs.com